RxDoctor Payments Data

Kashif Iqbal, MD

Internal Medicine · Evansville, INNPI 1942376074

Payments from drug & device makers

$8,943in general payments, 2019–2025

Across 606 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • GSK$971
  • Amgen$756
  • AstraZeneca$598
  • Merck$519
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,79598%
  • Education$1482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,943 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$130,900
Medicare patients
460
Services billed
2,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$121,196
EliquisApixaban120$108,839
FarxigaDapagliflozin Propanediol56$55,839
OzempicSemaglutide44$48,753
MounjaroTirzepatide27$29,958
RybelsusSemaglutide21$22,192
OxycontinOxycodone Hcl12$21,016
XareltoRivaroxaban15$15,977
Spiriva HandihalerTiotropium Bromide15$15,153
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$13,524
EntrestoSacubitril/Valsartan11$12,929
Spiriva RespimatTiotropium Bromide17$10,148
GlyxambiEmpagliflozin/Linagliptin12$7,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$7,109
SymbicortBudesonide/Formoterol Fumarate31$7,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Glyxambi$278$152,199181 claims
PfizerEliquis$186$108,839120 claims
Novo NordiskOzempic, Rybelsus$1,063$70,94565 claims
AstraZenecaFarxiga, Symbicort$598$62,94187 claims
Lilly USA, LLCMounjaro$305$29,95827 claims
Johnson & JohnsonXarelto$86$15,97715 claims
NovartisEntresto$202$12,92911 claims
Astellas Pharma US IncMyrbetriq$205$5,60812 claims
GSKBreo Ellipta$971$5,56212 claims
AbbVieSynthroid$1,255$2,36927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →